5-year PROFILE data: Top-down therapy able to modify longer-term course of CD
17 May 2026
byJairia Dela Cruz
A top-down approach of initiating treatment with infliximab plus immunomodulator upon diagnosis of Crohn’s disease (CD) reduces the risk of related abdominal surgery, as well as those of disease progression and hospitalization, as compared with the conventional step-up approach, according to long-term data from the PROFILE trial.
